An Excellent Target with a Wide Therapeutic Window in del(5q) Myeloid Malignancies

The aim of this study was to identify novel molecular vulnerabilities in del (5q), Deletion of the long arm of chromosome 5, one of the most common chromosomal alterations in myeloid malignancies. In this MEDtalk from EHA 2024, Sergio Martinez Høyer, research specialist at Karolinska Institutet, Sweden, explains why RBM22 is an excellent target with a wide therapeutic window in del (5q)myeloid neoplasms.